Search results
Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma...
Benzinga via AOL· 1 day agoMonday, Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc (NYSE:MRK) announced the first presentation of...
FDA sets review date for Merck's KEYTRUDA in mesothelioma treatment By Investing.com
Investing.com· 6 days agoMerck & Co., Inc., a global healthcare leader, has announced that the U.S. Food and Drug...
Merck Reportedly Nearing $1.3B Acquisition Of EyeBio To Expand Eye-Care Market Presence - Merck & Co...
Benzinga· 7 days agoMerck & Co., Inc. MRK is reportedly on the verge of acquiring EyeBio, an eye drug company, for a sum...
Merck (NYSE:MRK) Seems To Use Debt Quite Sensibly
Simply Wall St. via Yahoo Finance· 3 days agoWhen we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to ruin. We can see that Merck & Co.
Merck acquires EyeBio in up to $3B deal By Proactive Investors
Investing.com· 6 days agoMerck & Co Inc (NYSE:MRK, ETR:6MK) announced it is acquiring Eyebio, a privately held...
Merck (MRK) to Buy Private Ophthalmology Company EyeBio
Zacks via Yahoo Finance· 5 days agoMerck's (MRK) acquisition of EyeBio is set to add the latter's lead pipeline candidate, Restoret, a...
Moderna-Merck skin cancer vaccine shows survival benefit in long-term follow-up
Reuters· 1 day ago, opens new tab said on Monday their cancer vaccine in combination with blockbuster cancer therapy...
Merck to buy EyeBio in a deal that could valued at up to $3 billion
Morningstar· 6 days agoMerck & Co. Inc. (MRK) announced Wednesday an agreement to buy privately held Eyebiotech Ltd., an ophthalmology-focused biotechnology ...
Summit Therapeutics stock rallies as institutional buyer loads up on shares | Invezz
Invezz· 1 day agoSummit Therapeutics Inc (NASDAQ: SMMT) says it raised $200 million via an offer it accepted from an...
Summit Therapeutics’ stock surges as lung-cancer treatment vies with Merck’s blockbuster
Market Watch· 5 days agojumped more than 270% Thursday after the company said its experimental cancer drug outperformed ...
